# s_type = frag
# newdoc id = AMALGUM_academic_braf
# sent_id = AMALGUM_academic_braf-1
# text = 4.
1	4.	4.	PROPN	NNP	Number=Sing	0	root	0:root	Discourse=preparation:1->3

# s_type = frag
# sent_id = AMALGUM_academic_braf-2
# text = Materials and Methods
1	Materials	material	NOUN	NNS	Number=Plur	0	root	0:root	Discourse=preparation:2->3|Entity=(abstract-1)
2	and	and	CCONJ	CC	_	3	cc	3:cc	_
3	Methods	method	NOUN	NNS	Number=Plur	1	conj	1:conj:and	Entity=(object-2)

# s_type = decl
# sent_id = AMALGUM_academic_braf-3
# text = A search was performed of regulatory and scientific literature to identify sources of clinical data to be used to compare the efficacy and safety of BRAFi/MEKi combination therapies for the treatment of BRAF -mutant metastatic melanoma .
1	A	a	DET	DT	Definite=Ind|PronType=Art	2	det	2:det	Discourse=ROOT:3|Entity=(event-3
2	search	search	NOUN	NN	Number=Sing	4	nsubj:pass	4:nsubj:pass	Entity=event-3)
3	was	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	4	aux:pass	4:aux:pass	_
4	performed	perform	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
5	of	of	ADP	IN	_	9	case	9:case	_
6	regulatory	regulatory	ADJ	JJ	Degree=Pos	9	amod	9:amod	Entity=(abstract-4
7	and	and	CCONJ	CC	_	8	cc	8:cc	_
8	scientific	scientific	ADJ	JJ	Degree=Pos	6	conj	6:conj:and|9:amod	_
9	literature	literature	NOUN	NN	Number=Sing	4	obl	4:obl:of	Entity=abstract-4)
10	to	to	PART	TO	_	11	mark	11:mark	Discourse=purpose:4->3
11	identify	identify	VERB	VB	VerbForm=Inf	4	advcl	4:advcl:to	_
12	sources	source	NOUN	NNS	Number=Plur	11	obj	11:obj	Entity=(abstract-5
13	of	of	ADP	IN	_	15	case	15:case	_
14	clinical	clinical	ADJ	JJ	Degree=Pos	15	amod	15:amod	Entity=(abstract-6
15	data	datum	NOUN	NNS	Number=Plur	12	nmod	12:nmod:of	_
16	to	to	PART	TO	_	18	mark	18:mark	Discourse=purpose:5->4
17	be	be	AUX	VB	VerbForm=Inf	18	aux:pass	18:aux:pass	_
18	used	use	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	15	acl	15:acl:to	_
19	to	to	PART	TO	_	20	mark	20:mark	Discourse=purpose:6->3
20	compare	compare	VERB	VB	VerbForm=Inf	18	xcomp	18:xcomp	_
21	the	the	DET	DT	Definite=Def|PronType=Art	22	det	22:det	Entity=(abstract-7
22	efficacy	efficacy	NOUN	NN	Number=Sing	20	obj	20:obj	Entity=abstract-7)
23	and	and	CCONJ	CC	_	24	cc	24:cc	_
24	safety	safety	NOUN	NN	Number=Sing	22	conj	20:obj|22:conj:and	Entity=(abstract-8
25	of	of	ADP	IN	_	28	case	28:case	_
26	BRAFi/MEKi	Brafirmeki	PROPN	NNP	Number=Sing	28	compound	28:compound	Entity=(abstract-9(abstract-10)
27	combination	combination	NOUN	NN	Number=Sing	28	compound	28:compound	Entity=(abstract-11)
28	therapies	therapy	NOUN	NNS	Number=Plur	22	nmod	22:nmod:of	Entity=abstract-5)abstract-6)abstract-8)abstract-9)
29	for	for	ADP	IN	_	31	case	31:case	_
30	the	the	DET	DT	Definite=Def|PronType=Art	31	det	31:det	Entity=(event-12
31	treatment	treatment	NOUN	NN	Number=Sing	20	obl	20:obl:for	_
32	of	of	ADP	IN	_	36	case	36:case	_
33	BRAF	Braf	PROPN	NNP	Number=Sing	34	compound	34:compound	Entity=(abstract-13(abstract-14)
34	-mutant	-mutant	NOUN	NN	Number=Sing	36	amod	36:amod	_
35	metastatic	metastatic	ADJ	JJ	Degree=Pos	36	amod	36:amod	_
36	melanoma	melanoma	NOUN	NN	Number=Sing	31	nmod	31:nmod:of	Entity=event-12)abstract-13)
37	.	.	PUNCT	.	_	4	punct	4:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-4
# text = The full details of the literature search are outlined in Table S4 .
1	The	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	Discourse=joint:7->3|Entity=(abstract-15
2	full	full	ADJ	JJ	Degree=Pos	3	amod	3:amod	_
3	details	detail	NOUN	NNS	Number=Plur	9	nsubj:pass	9:nsubj:pass	_
4	of	of	ADP	IN	_	7	case	7:case	_
5	the	the	DET	DT	Definite=Def|PronType=Art	7	det	7:det	Entity=(event-3
6	literature	literature	NOUN	NN	Number=Sing	7	compound	7:compound	Entity=(abstract-4)
7	search	search	NOUN	NN	Number=Sing	3	nmod	3:nmod:of	Entity=abstract-15)event-3)
8	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	9	aux:pass	9:aux:pass	_
9	outlined	outline	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
10	in	in	ADP	IN	_	11	case	11:case	_
11	Table	Table	PROPN	NNP	Number=Sing	9	obl	9:obl:in	Entity=(abstract-16)
12	S4	S4	PROPN	NNP	Number=Sing	11	dep	11:dep	Entity=(abstract-17)
13	.	.	PUNCT	.	_	9	punct	9:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-5
# text = Four phase III studies were identified : coBRIM , a phase III trial of cobimetinib plus vemurafenib versus vemurafenib monotherapy in previously untreated patients with advanced BRAF -mutant melanoma ; COMBI-d , a phase III trial of dabrafenib and trametinib versus dabrafenib monotherapy in previously untreated patients with unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation ; COMBI-v , a phase III trial of dabrafenib plus trametinib versus vemurafenib monotherapy in previously untreated patients with unresectable stage IIIC or IV melanoma with BRAF mutation ; and COLUMBUS Part 1 , a phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib monotherapy in patients with BRAF -mutant melanoma .
1	Four	4	NUM	CD	NumForm=Digit|NumType=Card	4	nummod	4:nummod	Discourse=preparation:8->9|Entity=(abstract-18
2	phase	phase	NOUN	NN	Number=Sing	4	compound	4:compound	Entity=(abstract-19
3	III	III	NUM	CD	NumForm=Roman|NumType=Card	2	flat	2:flat	Entity=abstract-19)
4	studies	study	NOUN	NNS	Number=Plur	6	nsubj:pass	6:nsubj:pass	Entity=abstract-18)
5	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	6	aux:pass	6:aux:pass	_
6	identified	identify	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
7	:	:	PUNCT	:	_	8	punct	8:punct	_
8	coBRIM	coBRIM	PROPN	NNP	Number=Sing	6	parataxis	6:parataxis	Discourse=joint:9->3|Entity=(abstract-20)
9	,	,	PUNCT	,	_	13	punct	13:punct	_
10	a	a	DET	DT	Definite=Ind|PronType=Art	13	det	13:det	Entity=(event-21
11	phase	phase	NOUN	NN	Number=Sing	12	compound	12:compound	Entity=(person-22(abstract-19)
12	III	III	PROPN	NNP	Number=Sing	13	compound	13:compound	Entity=person-22)
13	trial	trial	NOUN	NN	Number=Sing	8	appos	8:appos	_
14	of	of	ADP	IN	_	15	case	15:case	_
15	cobimetinib	cobimetinib	NOUN	NN	Number=Sing	13	nmod	13:nmod:of	Entity=(abstract-23(substance-24)
16	plus	plus	CCONJ	CC	_	17	cc	17:cc	_
17	vemurafenib	vemurafenib	NOUN	NN	Number=Sing	15	conj	13:nmod:of|15:conj:plus	Entity=(person-25
18	versus	versus	ADP	IN	_	20	case	20:case	_
19	vemurafenib	vemurafenib	NOUN	NN	Number=Sing	20	compound	20:compound	Entity=(abstract-26(person-25)
20	monotherapy	monotherapy	NOUN	NN	Number=Sing	15	nmod	15:nmod:versus	_
21	in	in	ADP	IN	_	24	case	24:case	_
22	previously	previously	ADV	RB	Degree=Pos	23	advmod	23:advmod	Entity=(person-27
23	untreated	untreated	ADJ	JJ	Degree=Pos|Polarity=Neg	24	amod	24:amod	_
24	patients	patient	NOUN	NNS	Number=Plur	20	nmod	20:nmod:in	_
25	with	with	ADP	IN	_	29	case	29:case	_
26	advanced	advanced	ADJ	JJ	Degree=Pos	29	amod	29:amod	Entity=(abstract-13
27	BRAF	Braf	PROPN	NNP	Number=Sing	28	compound	28:compound	Entity=(abstract-14)
28	-mutant	-mutant	NOUN	NN	Number=Sing	29	amod	29:amod	_
29	melanoma	melanoma	NOUN	NN	Number=Sing	24	nmod	24:nmod:with	Entity=event-21)abstract-23)person-25)abstract-26)person-27)abstract-13)
30	;	;	PUNCT	:	_	31	punct	31:punct	_
31	COMBI-d	COMBI-d	PROPN	NNP	Number=Sing	8	conj	8:conj:and	Discourse=elaboration:10->9|Entity=(abstract-28)
32	,	,	PUNCT	,	_	36	punct	36:punct	_
33	a	a	DET	DT	Definite=Ind|PronType=Art	36	det	36:det	Entity=(event-29
34	phase	phase	NOUN	NN	Number=Sing	35	compound	35:compound	Entity=(abstract-19)
35	III	III	ADJ	NNP	Number=Sing	36	amod	36:amod	_
36	trial	trial	NOUN	NN	Number=Sing	31	appos	31:appos	_
37	of	of	ADP	IN	_	38	case	38:case	_
38	dabrafenib	dabrafenib	NOUN	NN	Number=Sing	36	nmod	36:nmod:of	Entity=(animal-30)
39	and	and	CCONJ	CC	_	40	cc	40:cc	_
40	trametinib	trametinib	NOUN	NN	Number=Sing	38	conj	36:nmod:of|38:conj:and	Entity=(object-31)
41	versus	versus	ADP	IN	_	43	case	43:case	_
42	dabrafenib	dabrafenib	PROPN	NNP	Number=Sing	43	compound	43:compound	Entity=(abstract-26(animal-30)
43	monotherapy	monotherapy	NOUN	NN	Number=Sing	36	nmod	36:nmod:versus	_
44	in	in	ADP	IN	_	47	case	47:case	_
45	previously	previously	ADV	RB	Degree=Pos	46	advmod	46:advmod	Entity=(person-27
46	untreated	untreated	ADJ	JJ	Degree=Pos|Polarity=Neg	47	amod	47:amod	_
47	patients	patient	NOUN	NNS	Number=Plur	43	nmod	43:nmod:in	_
48	with	with	ADP	IN	_	55	case	55:case	_
49	unresectable	unresectable	ADJ	JJ	Degree=Pos|Polarity=Neg	55	amod	55:amod	Entity=(abstract-13
50	stage	stage	NOUN	NN	Number=Sing	51	compound	51:compound	Entity=(abstract-32(abstract-33(abstract-34)
51	IIIC	IIIC	NOUN	NN	Number=Sing	55	compound	55:compound	Entity=abstract-33)
52	or	or	CCONJ	CC	_	54	cc	54:cc	_
53	stage	stage	NOUN	NN	Number=Sing	54	compound	54:compound	Entity=(place-35
54	IV	IV	NOUN	NN	Number=Sing	51	conj	51:conj:or|55:compound	Entity=abstract-32)place-35)
55	melanoma	melanoma	NOUN	NN	Number=Sing	47	nmod	47:nmod:with	_
56	with	with	ADP	IN	_	62	case	62:case	_
57	a	a	DET	DT	Definite=Ind|PronType=Art	62	det	62:det	Entity=(abstract-36
58	BRAF	Braf	PROPN	NNP	Number=Sing	62	compound	62:compound	Entity=(person-37)
59	V600E	V600E	NUM	CD	NumForm=Word|NumType=Card	62	compound	62:compound	_
60	or	or	CCONJ	CC	_	61	cc	61:cc	_
61	V600K	V600K	NOUN	NN	Number=Sing	59	conj	59:conj:or|62:compound	Entity=(person-38)
62	mutation	mutation	NOUN	NN	Number=Sing	55	nmod	55:nmod:with	Entity=event-29)abstract-26)person-27)abstract-13)abstract-36)
63	;	;	PUNCT	:	_	64	punct	64:punct	_
64	COMBI-v	COMBI-v	PROPN	NNP	Number=Sing	8	conj	8:conj:plus	Discourse=joint:11->10|Entity=(abstract-39)
65	,	,	PUNCT	,	_	69	punct	69:punct	_
66	a	a	DET	DT	Definite=Ind|PronType=Art	69	det	69:det	_
67	phase	phase	NOUN	NN	Number=Sing	69	compound	69:compound	Entity=(abstract-19)
68	III	III	ADJ	NNP	Number=Sing	69	amod	69:amod	_
69	trial	trial	NOUN	NN	Number=Sing	64	dep	64:dep	_
70	of	of	ADP	IN	_	71	case	71:case	_
71	dabrafenib	dabrafenib	NOUN	NN	Number=Sing	69	nmod	69:nmod:of	Entity=(animal-30)
72	plus	plus	CCONJ	CC	_	73	cc	73:cc	_
73	trametinib	trametinib	NOUN	NN	Number=Sing	71	conj	69:nmod:of|71:conj:plus	Entity=(object-31
74	versus	versus	ADP	IN	_	76	case	76:case	_
75	vemurafenib	vemurafenib	NOUN	NN	Number=Sing	76	compound	76:compound	Entity=(abstract-26(person-25)
76	monotherapy	monotherapy	NOUN	NN	Number=Sing	71	nmod	71:nmod:versus	Entity=object-31)abstract-26)
77	in	in	ADP	IN	_	80	case	80:case	_
78	previously	previously	ADV	RB	Degree=Pos	79	advmod	79:advmod	Entity=(person-27
79	untreated	untreated	ADJ	JJ	Degree=Pos|Polarity=Neg	80	amod	80:amod	_
80	patients	patient	NOUN	NNS	Number=Plur	69	nmod	69:nmod:in	_
81	with	with	ADP	IN	_	87	case	87:case	_
82	unresectable	unresectable	ADJ	JJ	Degree=Pos|Polarity=Neg	87	amod	87:amod	Entity=(abstract-13
83	stage	stage	NOUN	NN	Number=Sing	84	compound	84:compound	Entity=(abstract-32(abstract-33(abstract-34)
84	IIIC	IIIC	PROPN	NNP	Number=Sing	87	compound	87:compound	Entity=abstract-33)
85	or	or	CCONJ	CC	_	86	cc	86:cc	_
86	IV	IV	NOUN	NN	Number=Sing	84	conj	84:conj:or|87:compound	Entity=abstract-32)(place-35)
87	melanoma	melanoma	NOUN	NN	Number=Sing	80	nmod	80:nmod:with	_
88	with	with	ADP	IN	_	90	case	90:case	_
89	BRAF	Braf	PROPN	NNP	Number=Sing	90	compound	90:compound	Entity=(abstract-36(person-37)
90	mutation	mutation	NOUN	NN	Number=Sing	87	nmod	87:nmod:with	Entity=person-27)abstract-13)abstract-36)
91	;	;	PUNCT	:	_	94	punct	94:punct	_
92	and	and	CCONJ	CC	_	94	cc	94:cc	Discourse=joint:12->11
93	COLUMBUS	Columbus	PROPN	NNP	Number=Sing	94	compound	94:compound	Entity=(abstract-40
94	Part	part	PROPN	NNP	Number=Sing	8	conj	8:conj:and	_
95	1	1	NUM	CD	NumForm=Digit|NumType=Card	94	dep	94:dep	Entity=abstract-40)
96	,	,	PUNCT	,	_	100	punct	100:punct	_
97	a	a	DET	DT	Definite=Ind|PronType=Art	100	det	100:det	Entity=(event-41
98	phase	phase	NOUN	NN	Number=Sing	100	compound	100:compound	Entity=(abstract-19
99	III	III	PROPN	NNP	Number=Sing	98	flat	98:flat	Entity=abstract-19)
100	trial	trial	NOUN	NN	Number=Sing	94	appos	94:appos	_
101	of	of	ADP	IN	_	102	case	102:case	_
102	encorafenib	encorafenib	NOUN	NN	Number=Sing	100	nmod	100:nmod:of	Entity=(abstract-42)
103	plus	plus	CCONJ	CC	_	104	cc	104:cc	_
104	binimetinib	binimetinib	NOUN	NN	Number=Sing	102	conj	100:nmod:of|102:conj:plus	Entity=(abstract-43
105	versus	versus	ADP	IN	_	106	case	106:case	_
106	vemurafenib	vemurafenib	NOUN	NN	Number=Sing	102	nmod	102:nmod:versus	Entity=abstract-43)(person-25)
107	or	or	CCONJ	CC	_	109	cc	109:cc	_
108	encorafenib	encorafenib	PROPN	NNP	Number=Sing	109	compound	109:compound	Entity=(abstract-26(abstract-42)
109	monotherapy	monotherapy	NOUN	NN	Number=Sing	102	conj	100:nmod:of|102:conj:or	Entity=abstract-26)
110	in	in	ADP	IN	_	111	case	111:case	_
111	patients	patient	NOUN	NNS	Number=Plur	100	nmod	100:nmod:in	Entity=(person-27
112	with	with	ADP	IN	_	115	case	115:case	_
113	BRAF	Braf	PROPN	NNP	Number=Sing	115	compound	115:compound	Entity=(abstract-13(person-37)
114	-mutant	-mutant	ADJ	JJ	Degree=Pos	115	amod	115:amod	_
115	melanoma	melanoma	NOUN	NN	Number=Sing	111	nmod	111:nmod:with	Entity=event-41)person-27)abstract-13)
116	.	.	PUNCT	.	_	6	punct	6:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-6
# text = Three of the identified studies ( coBRIM , COMBI-v , and COLUMBUS Part 1 ) , had vemurafenib 960 mg twice daily ( BID ) as a control arm , and were the chief sources of data for the comparisons presented here .
1	Three	3	NUM	CD	NumForm=Digit|NumType=Card	17	nsubj	17:nsubj	Discourse=joint:13->9|Entity=(abstract-44
2	of	of	ADP	IN	_	5	case	5:case	_
3	the	the	DET	DT	Definite=Def|PronType=Art	5	det	5:det	Entity=(abstract-18
4	identified	identify	VERB	VBN	Tense=Past|VerbForm=Part	5	amod	5:amod	_
5	studies	study	NOUN	NNS	Number=Plur	1	nmod	1:nmod:of	Entity=abstract-44)abstract-18)
6	(	(	PUNCT	-LRB-	_	7	punct	7:punct	Discourse=elaboration:14->13
7	coBRIM	coBRIM	PROPN	NNP	Number=Sing	5	appos	5:appos	Entity=(abstract-18(abstract-20)
8	,	,	PUNCT	,	_	9	punct	9:punct	_
9	COMBI-v	COMBI-v	PROPN	NNP	Number=Sing	7	conj	5:appos|7:conj:and	Entity=(abstract-39)
10	,	,	PUNCT	,	_	13	punct	13:punct	_
11	and	and	CCONJ	CC	_	13	cc	13:cc	_
12	COLUMBUS	Columbus	PROPN	NNP	Number=Sing	13	compound	13:compound	Entity=(abstract-40
13	Part	part	PROPN	NNP	Number=Sing	7	conj	5:appos|7:conj:and	_
14	1	1	NUM	CD	NumForm=Digit|NumType=Card	13	dep	13:dep	Entity=abstract-18)abstract-40)
15	)	)	PUNCT	-RRB-	_	7	punct	7:punct	_
16	,	,	PUNCT	,	_	1	punct	1:punct	_
17	had	have	VERB	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	0	root	0:root	Discourse=same_unit:15->13
18	vemurafenib	vemurafenib	NOUN	NN	Number=Sing	20	compound	20:compound	Entity=(substance-45(person-25)
19	960	960	NUM	CD	NumForm=Digit|NumType=Card	20	nummod	20:nummod	_
20	mg	mgillileter	NOUN	NN	Number=Sing	17	obj	17:obj	Entity=substance-45)
21	twice	twice	ADV	RB	NumType=Mult	22	advmod	22:advmod	_
22	daily	daily	ADV	RB	Degree=Pos	17	advmod	17:advmod	_
23	(	(	PUNCT	-LRB-	_	24	punct	24:punct	Discourse=restatement:16->15
24	BID	BID	PROPN	NNP	Number=Sing	22	appos	22:appos	Entity=(abstract-46)
25	)	)	PUNCT	-RRB-	_	24	punct	24:punct	_
26	as	as	ADP	IN	_	29	case	29:case	Discourse=same_unit:17->15
27	a	a	DET	DT	Definite=Ind|PronType=Art	29	det	29:det	Entity=(object-47
28	control	control	NOUN	NN	Number=Sing	29	compound	29:compound	Entity=(abstract-48)
29	arm	arm	NOUN	NN	Number=Sing	17	obl	17:obl:as	Entity=object-47)
30	,	,	PUNCT	,	_	35	punct	35:punct	_
31	and	and	CCONJ	CC	_	35	cc	35:cc	Discourse=joint:18->9
32	were	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	35	cop	35:cop	_
33	the	the	DET	DT	Definite=Def|PronType=Art	35	det	35:det	Entity=(abstract-49
34	chief	chief	ADJ	JJ	Degree=Pos	35	amod	35:amod	_
35	sources	source	NOUN	NNS	Number=Plur	17	conj	17:conj:and	_
36	of	of	ADP	IN	_	37	case	37:case	_
37	data	datum	NOUN	NNS	Number=Plur	35	nmod	35:nmod:of	Entity=(abstract-6)
38	for	for	ADP	IN	_	40	case	40:case	_
39	the	the	DET	DT	Definite=Def|PronType=Art	40	det	40:det	Entity=(abstract-50
40	comparisons	comparison	NOUN	NNS	Number=Plur	35	nmod	35:nmod:for	_
41	presented	present	VERB	VBN	Tense=Past|VerbForm=Part	40	acl	40:acl	Discourse=elaboration:19->18
42	here	here	ADV	RB	PronType=Dem	41	advmod	41:advmod	Entity=abstract-49)abstract-50)
43	.	.	PUNCT	.	_	17	punct	17:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-7
# text = Although the COMBI-d was identified as part of the initial literature search , it was not included in the efficacy comparison of the cross-trial comparison due to the lack of a vemurafenib control arm .
1	Although	although	SCONJ	IN	_	5	mark	5:mark	Discourse=concession:20->21
2	the	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	Entity=(abstract-28
3	COMBI-d	COMBI-d	PROPN	NNP	Number=Sing	5	nsubj:pass	5:nsubj:pass	Entity=abstract-28)
4	was	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	5	aux:pass	5:aux:pass	_
5	identified	identify	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	17	advcl	17:advcl:although	_
6	as	as	ADP	IN	_	7	case	7:case	_
7	part	part	NOUN	NN	Number=Sing	5	obl	5:obl:as	_
8	of	of	ADP	IN	_	12	case	12:case	_
9	the	the	DET	DT	Definite=Def|PronType=Art	12	det	12:det	Entity=(event-3
10	initial	initial	ADJ	JJ	Degree=Pos	12	amod	12:amod	_
11	literature	literature	NOUN	NN	Number=Sing	12	compound	12:compound	Entity=(abstract-4)
12	search	search	NOUN	NN	Number=Sing	7	nmod	7:nmod:of	Entity=event-3)
13	,	,	PUNCT	,	_	5	punct	5:punct	_
14	it	it	PRON	PRP	Case=Nom|Gender=Neut|Number=Sing|Person=3|PronType=Prs	17	nsubj:pass	17:nsubj:pass	Discourse=joint:21->9|Entity=(abstract-28)
15	was	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	17	aux:pass	17:aux:pass	_
16	not	not	ADV	RB	Polarity=Neg	17	advmod	17:advmod	_
17	included	include	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
18	in	in	ADP	IN	_	21	case	21:case	_
19	the	the	DET	DT	Definite=Def|PronType=Art	21	det	21:det	Entity=(abstract-51
20	efficacy	efficacy	NOUN	NN	Number=Sing	21	compound	21:compound	Entity=(abstract-7)
21	comparison	comparison	NOUN	NN	Number=Sing	17	obl	17:obl:in	_
22	of	of	ADP	IN	_	25	case	25:case	_
23	the	the	DET	DT	Definite=Def|PronType=Art	25	det	25:det	Entity=(abstract-51
24	cross-trial	cross-trial	ADJ	JJ	Degree=Pos	25	amod	25:amod	_
25	comparison	comparison	NOUN	NN	Number=Sing	21	nmod	21:nmod:of	Entity=abstract-51)abstract-51)
26	due	due	ADJ	JJ	Degree=Pos	29	case	29:case	Discourse=elaboration:22->21
27	to	to	ADP	IN	_	26	fixed	26:fixed	_
28	the	the	DET	DT	Definite=Def|PronType=Art	29	det	29:det	Entity=(abstract-52
29	lack	lack	NOUN	NN	Number=Sing	17	obl	17:obl:due_to	_
30	of	of	ADP	IN	_	34	case	34:case	_
31	a	a	DET	DT	Definite=Ind|PronType=Art	34	det	34:det	Entity=(object-47
32	vemurafenib	vemurafenib	NOUN	NN	Number=Sing	34	compound	34:compound	Entity=(person-25)
33	control	control	NOUN	NN	Number=Sing	34	compound	34:compound	Entity=(abstract-48)
34	arm	arm	NOUN	NN	Number=Sing	29	nmod	29:nmod:of	Entity=abstract-52)object-47)
35	.	.	PUNCT	.	_	17	punct	17:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-8
# text = It should be noted , however , that the outcomes in COMBI-d were substantially similar to those in COMBI-v .
1	It	it	PRON	PRP	Case=Acc|Gender=Neut|Number=Sing|Person=3|PronType=Prs	4	expl	4:expl	Discourse=attribution:23->24|Entity=(abstract-52)
2	should	should	AUX	MD	VerbForm=Fin	4	aux	4:aux	_
3	be	be	AUX	VB	VerbForm=Inf	4	aux:pass	4:aux:pass	_
4	noted	note	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
5	,	,	PUNCT	,	_	6	punct	6:punct	_
6	however	however	ADV	RB	_	4	advmod	4:advmod	_
7	,	,	PUNCT	,	_	15	punct	15:punct	_
8	that	that	SCONJ	IN	_	15	mark	15:mark	Discourse=elaboration:24->21
9	the	the	DET	DT	Definite=Def|PronType=Art	10	det	10:det	Entity=(abstract-53
10	outcomes	outcome	NOUN	NNS	Number=Plur	15	nsubj	15:nsubj	_
11	in	in	ADP	IN	_	12	case	12:case	_
12	COMBI-d	COMBI-d	PROPN	NNP	Number=Sing	10	nmod	10:nmod:in	Entity=abstract-53)(abstract-28)
13	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	15	cop	15:cop	_
14	substantially	substantially	ADV	RB	Degree=Pos	15	advmod	15:advmod	_
15	similar	similar	ADJ	JJ	Degree=Pos	4	csubj:pass	4:csubj:pass	_
16	to	to	ADP	IN	_	17	case	17:case	_
17	those	this	PRON	DT	Number=Plur|PronType=Dem	15	obl	15:obl:to	Entity=(abstract-52
18	in	in	ADP	IN	_	19	case	19:case	_
19	COMBI-v	COMBI-v	PROPN	NNP	Number=Sing	17	nmod	17:nmod:in	Entity=abstract-52)(abstract-39)
20	.	.	PUNCT	.	_	4	punct	4:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-9
# text = The key design features of the three included phase III trials are summarized in Table 5 .
1	The	the	DET	DT	Definite=Def|PronType=Art	4	det	4:det	Discourse=joint:25->24|Entity=(abstract-54
2	key	key	ADJ	JJ	Degree=Pos	4	amod	4:amod	_
3	design	design	NOUN	NN	Number=Sing	4	compound	4:compound	Entity=(abstract-55)
4	features	feature	NOUN	NNS	Number=Plur	13	nsubj:pass	13:nsubj:pass	_
5	of	of	ADP	IN	_	11	case	11:case	_
6	the	the	DET	DT	Definite=Def|PronType=Art	11	det	11:det	Entity=(event-56
7	three	3	NUM	CD	NumForm=Digit|NumType=Card	11	nummod	11:nummod	_
8	included	include	VERB	VBN	Tense=Past|VerbForm=Part	11	amod	11:amod	_
9	phase	phase	NOUN	NN	Number=Sing	11	compound	11:compound	Entity=(abstract-19)
10	III	III	NUM	CD	NumForm=Roman|NumType=Card	11	compound	11:compound	_
11	trials	trial	NOUN	NNS	Number=Plur	4	nmod	4:nmod:of	Entity=abstract-54)event-56)
12	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	13	aux:pass	13:aux:pass	_
13	summarized	summarize	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
14	in	in	ADP	IN	_	15	case	15:case	_
15	Table	Table	PROPN	NNP	Number=Sing	13	obl	13:obl:in	Entity=(abstract-16
16	5	5	NUM	CD	NumForm=Digit|NumType=Card	15	dep	15:dep	Entity=abstract-16)
17	.	.	PUNCT	.	_	13	punct	13:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-10
# text = To assist with the completeness of the cross-trial comparison , medical information requests were made to the registered sponsor of cobimetinib , vemurafenib , dabrafenib , trametinib , encorafenib , or binimetinib if any missing data were identified .
1	To	to	PART	TO	_	2	mark	2:mark	Discourse=purpose:26->25
2	assist	assist	VERB	VB	VerbForm=Inf	15	advcl	15:advcl:to	_
3	with	with	ADP	IN	_	5	case	5:case	_
4	the	the	DET	DT	Definite=Def|PronType=Art	5	det	5:det	_
5	completeness	completeness	NOUN	NN	Number=Sing	2	obl	2:obl:with	_
6	of	of	ADP	IN	_	9	case	9:case	_
7	the	the	DET	DT	Definite=Def|PronType=Art	9	det	9:det	Entity=(abstract-51
8	cross-trial	cross-trial	ADJ	JJ	Degree=Pos	9	amod	9:amod	_
9	comparison	comparison	NOUN	NN	Number=Sing	5	nmod	5:nmod:of	Entity=abstract-51)
10	,	,	PUNCT	,	_	2	punct	2:punct	_
11	medical	medical	ADJ	JJ	Degree=Pos	13	amod	13:amod	Entity=(abstract-57
12	information	information	NOUN	NN	Number=Sing	13	compound	13:compound	Entity=(abstract-58)
13	requests	request	NOUN	NNS	Number=Plur	15	nsubj:pass	15:nsubj:pass	Entity=abstract-57)
14	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	15	aux:pass	15:aux:pass	_
15	made	make	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
16	to	to	ADP	IN	_	19	case	19:case	_
17	the	the	DET	DT	Definite=Def|PronType=Art	19	det	19:det	Entity=(person-59
18	registered	register	VERB	VBN	Tense=Past|VerbForm=Part	19	amod	19:amod	_
19	sponsor	sponsor	NOUN	NN	Number=Sing	15	obl	15:obl:to	_
20	of	of	ADP	IN	_	21	case	21:case	_
21	cobimetinib	cobimetinib	NOUN	NN	Number=Sing	19	nmod	19:nmod:of	Entity=(substance-24)
22	,	,	PUNCT	,	_	23	punct	23:punct	_
23	vemurafenib	vemurafenib	NOUN	NN	Number=Sing	21	conj	19:nmod:of|21:conj:or	Entity=(abstract-60)
24	,	,	PUNCT	,	_	25	punct	25:punct	_
25	dabrafenib	dabrafenib	NOUN	NN	Number=Sing	21	conj	19:nmod:of|21:conj:or	Entity=(animal-30)
26	,	,	PUNCT	,	_	27	punct	27:punct	_
27	trametinib	trametinib	NOUN	NN	Number=Sing	21	conj	19:nmod:of|21:conj:or	Entity=(object-31)
28	,	,	PUNCT	,	_	29	punct	29:punct	_
29	encorafenib	encorafenib	NOUN	NN	Number=Sing	21	conj	19:nmod:of|21:conj:or	Entity=(abstract-42)
30	,	,	PUNCT	,	_	32	punct	32:punct	_
31	or	or	CCONJ	CC	_	32	cc	32:cc	_
32	binimetinib	binimetinib	NOUN	NN	Number=Sing	21	conj	19:nmod:of|21:conj:or	Entity=person-59)(abstract-43)
33	if	if	SCONJ	IN	_	38	mark	38:mark	Discourse=condition:27->26
34	any	any	DET	DT	_	36	det	36:det	Entity=(abstract-6
35	missing	miss	ADJ	JJ	Degree=Pos	36	amod	36:amod	_
36	data	datum	NOUN	NNS	Number=Plur	38	nsubj:pass	38:nsubj:pass	Entity=abstract-6)
37	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	38	aux:pass	38:aux:pass	_
38	identified	identify	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	15	advcl	15:advcl:if	_
39	.	.	PUNCT	.	_	15	punct	15:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-11
# text = The data sources for the coBRIM and COMBI-v trials included primary and secondary publications of data , European public assessment reports ( EPAR ) , U.S. Food and Drug Administration ( FDA ) medical review documents , and the current U.S. prescribing information ( see Table S5 , which illustrates the data sources and cutoff dates for COMBI-v , coBRIM , and COLUMBUS trials ) .
1	The	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	Discourse=joint:28->9|Entity=(abstract-49
2	data	datum	NOUN	NNS	Number=Plur	3	compound	3:compound	Entity=(abstract-6)
3	sources	source	NOUN	NNS	Number=Plur	10	nsubj	10:nsubj	_
4	for	for	ADP	IN	_	9	case	9:case	_
5	the	the	DET	DT	Definite=Def|PronType=Art	9	det	9:det	Entity=(event-56
6	coBRIM	coBRIM	PROPN	NNP	Number=Sing	9	compound	9:compound	Entity=(abstract-20)
7	and	and	CCONJ	CC	_	8	cc	8:cc	_
8	COMBI-v	COMBI-v	PROPN	NNP	Number=Sing	6	conj	6:conj:and|9:compound	Entity=(abstract-39)
9	trials	trial	NOUN	NNS	Number=Plur	3	nmod	3:nmod:for	Entity=abstract-49)event-56)
10	included	include	VERB	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	0	root	0:root	_
11	primary	primary	ADJ	JJ	Degree=Pos	14	amod	14:amod	Entity=(organization-61
12	and	and	CCONJ	CC	_	13	cc	13:cc	_
13	secondary	secondary	ADJ	JJ	Degree=Pos	11	conj	11:conj:and|14:amod	_
14	publications	publication	NOUN	NNS	Number=Plur	10	obj	10:obj	_
15	of	of	ADP	IN	_	16	case	16:case	_
16	data	datum	NOUN	NNS	Number=Plur	14	nmod	14:nmod:of	Entity=organization-61)(abstract-6)
17	,	,	PUNCT	,	_	21	punct	21:punct	_
18	European	European	ADJ	JJ	Degree=Pos	21	amod	21:amod	Entity=(abstract-62
19	public	public	ADJ	JJ	Degree=Pos	20	amod	20:amod	Entity=(abstract-63
20	assessment	assessment	NOUN	NN	Number=Sing	21	compound	21:compound	Entity=abstract-63)
21	reports	report	NOUN	NNS	Number=Plur	14	conj	10:obj|14:conj:and	Entity=abstract-62)
22	(	(	PUNCT	-LRB-	_	23	punct	23:punct	Discourse=elaboration:29->28
23	EPAR	EPAR	PROPN	NNP	Number=Sing	21	appos	21:appos	Entity=(organization-64)
24	)	)	PUNCT	-RRB-	_	23	punct	23:punct	_
25	,	,	PUNCT	,	_	36	punct	36:punct	_
26	U.S.	U.S.	PROPN	NNP	Abbr=Yes|Number=Sing	30	compound	30:compound	Discourse=same_unit:30->28|Entity=(object-65(organization-66(place-67)
27	Food	Food	PROPN	NNP	Number=Sing	36	compound	36:compound	Entity=(object-68)
28	and	and	CCONJ	CC	_	29	cc	29:cc	_
29	Drug	Drug	PROPN	NNP	Number=Sing	27	conj	27:conj:and|36:compound	Entity=(substance-69)
30	Administration	Administration	PROPN	NNP	Number=Sing	36	compound	36:compound	Entity=organization-66)
31	(	(	PUNCT	-LRB-	_	32	punct	32:punct	Discourse=restatement:31->30
32	FDA	FDA	PROPN	NNP	Number=Sing	30	appos	30:appos	Entity=(organization-66)
33	)	)	PUNCT	-RRB-	_	32	punct	32:punct	_
34	medical	medical	ADJ	JJ	Degree=Pos	35	amod	35:amod	Discourse=same_unit:32->30|Entity=(abstract-70
35	review	review	NOUN	NN	Number=Sing	36	compound	36:compound	Entity=abstract-70)
36	documents	document	NOUN	NNS	Number=Plur	14	conj	10:obj|14:conj:and	Entity=object-65)
37	,	,	PUNCT	,	_	43	punct	43:punct	_
38	and	and	CCONJ	CC	_	43	cc	43:cc	_
39	the	the	DET	DT	Definite=Def|PronType=Art	43	det	43:det	Entity=(abstract-58
40	current	current	ADJ	JJ	Degree=Pos	43	amod	43:amod	_
41	U.S.	U.S.	PROPN	NNP	Abbr=Yes|Number=Sing	43	compound	43:compound	Entity=(place-67)
42	prescribing	prescribing	NOUN	NN	Number=Sing	43	compound	43:compound	Entity=(person-71)
43	information	information	NOUN	NN	Number=Sing	14	conj	10:obj|14:conj:and	Entity=abstract-58)
44	(	(	PUNCT	-LRB-	_	45	punct	45:punct	Discourse=elaboration:33->32
45	see	see	VERB	VB	Mood=Imp|Person=2|VerbForm=Fin	43	parataxis	43:parataxis	_
46	Table	Table	PROPN	NNP	Number=Sing	45	obj	45:obj|50:nsubj	Entity=(abstract-16
47	S5	S5	PROPN	NNP	Number=Sing	46	dep	46:dep	Entity=(abstract-72)
48	,	,	PUNCT	,	_	50	punct	50:punct	_
49	which	which	PRON	WDT	PronType=Rel	50	nsubj	46:ref	Discourse=elaboration:34->33
50	illustrates	illustrate	VERB	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	46	acl:relcl	46:acl:relcl	_
51	the	the	DET	DT	Definite=Def|PronType=Art	53	det	53:det	Entity=(abstract-49(abstract-49
52	data	datum	NOUN	NNS	Number=Plur	53	compound	53:compound	Entity=(abstract-6)
53	sources	source	NOUN	NNS	Number=Plur	50	obj	50:obj	Entity=abstract-49)
54	and	and	CCONJ	CC	_	56	cc	56:cc	_
55	cutoff	cutoff	NOUN	NN	Number=Sing	56	compound	56:compound	Entity=(time-73(abstract-74)
56	dates	date	NOUN	NNS	Number=Plur	53	conj	50:obj|53:conj:and	_
57	for	for	ADP	IN	_	64	case	64:case	_
58	COMBI-v	COMBI-v	PROPN	NNP	Number=Sing	64	compound	64:compound	Entity=(event-56(abstract-39)
59	,	,	PUNCT	,	_	60	punct	60:punct	_
60	coBRIM	coBRIM	PROPN	NNP	Number=Sing	58	conj	58:conj:and|64:compound	Entity=(abstract-20)
61	,	,	PUNCT	,	_	63	punct	63:punct	_
62	and	and	CCONJ	CC	_	63	cc	63:cc	_
63	COLUMBUS	Columbus	PROPN	NNP	Number=Sing	58	conj	58:conj:and|64:compound	Entity=(place-75)
64	trials	trial	NOUN	NNS	Number=Plur	56	nmod	56:nmod:for	Entity=abstract-16)abstract-49)time-73)event-56)
65	)	)	PUNCT	-RRB-	_	45	punct	45:punct	_
66	.	.	PUNCT	.	_	10	punct	10:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-12
# text = The data sources for the COLUMBUS trial include a primary publication , U.S. prescribing information , and Array BioPharma data on file .
1	The	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	Discourse=joint:35->9|Entity=(abstract-49
2	data	datum	NOUN	NNS	Number=Plur	3	compound	3:compound	Entity=(abstract-6)
3	sources	source	NOUN	NNS	Number=Plur	8	nsubj	8:nsubj	_
4	for	for	ADP	IN	_	7	case	7:case	_
5	the	the	DET	DT	Definite=Def|PronType=Art	7	det	7:det	Entity=(event-41
6	COLUMBUS	Columbus	PROPN	NNP	Number=Sing	7	compound	7:compound	Entity=(place-75)
7	trial	trial	NOUN	NN	Number=Sing	3	nmod	3:nmod:for	Entity=abstract-49)event-41)
8	include	include	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	_
9	a	a	DET	DT	Definite=Ind|PronType=Art	11	det	11:det	Entity=(abstract-76
10	primary	primary	ADJ	JJ	Degree=Pos	11	amod	11:amod	_
11	publication	publication	NOUN	NN	Number=Sing	8	obj	8:obj	Entity=abstract-76)
12	,	,	PUNCT	,	_	15	punct	15:punct	_
13	U.S.	U.S.	ADJ	NNP	Abbr=Yes|Number=Sing	15	amod	15:amod	Entity=(abstract-58
14	prescribing	prescribing	NOUN	NN	Number=Sing	15	compound	15:compound	Entity=(person-71)
15	information	information	NOUN	NN	Number=Sing	11	conj	8:obj|11:conj:and	Entity=abstract-58)
16	,	,	PUNCT	,	_	20	punct	20:punct	_
17	and	and	CCONJ	CC	_	20	cc	20:cc	_
18	Array	Array	PROPN	NNP	Number=Sing	20	compound	20:compound	Entity=(abstract-6(organization-77
19	BioPharma	BioPharma	PROPN	NNP	Number=Sing	20	compound	20:compound	Entity=organization-77)
20	data	datum	NOUN	NNS	Number=Plur	11	conj	8:obj|11:conj:and	_
21	on	on	ADP	IN	_	22	case	22:case	_
22	file	file	NOUN	NN	Number=Sing	20	nmod	20:nmod:on	Entity=abstract-6)(object-78)
23	.	.	PUNCT	.	_	8	punct	8:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-13
# text = The efficacy outcomes presented are PFS , objective response rate ( ORR ) , duration of response ( DOR ) per investigator assessment , and OS .
1	The	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	Discourse=elaboration:36->35|Entity=(abstract-53
2	efficacy	efficacy	NOUN	NN	Number=Sing	3	compound	3:compound	Entity=(abstract-7)
3	outcomes	outcome	NOUN	NNS	Number=Plur	6	nsubj	6:nsubj|10:nsubj|15:nsubj|26:nsubj	_
4	presented	present	VERB	VBN	Tense=Past|VerbForm=Part	3	acl	3:acl	Discourse=elaboration:37->36|Entity=abstract-53)
5	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	6	cop	6:cop	_
6	PFS	PFS	PROPN	NNP	Number=Sing	0	root	0:root	Entity=(abstract-53(abstract-53)
7	,	,	PUNCT	,	_	10	punct	10:punct	_
8	objective	objective	ADJ	JJ	Degree=Pos	10	amod	10:amod	Entity=(abstract-79
9	response	response	NOUN	NN	Number=Sing	10	compound	10:compound	Entity=(abstract-80)
10	rate	rate	NOUN	NN	Number=Sing	6	conj	6:conj:and	Entity=abstract-79)
11	(	(	PUNCT	-LRB-	_	12	punct	12:punct	Discourse=elaboration:38->37
12	ORR	ORR	PROPN	NNP	Number=Sing	10	appos	10:appos	Entity=(abstract-79)
13	)	)	PUNCT	-RRB-	_	12	punct	12:punct	_
14	,	,	PUNCT	,	_	15	punct	15:punct	_
15	duration	duration	NOUN	NN	Number=Sing	6	conj	6:conj:and	Discourse=same_unit:39->36|Entity=(time-81
16	of	of	ADP	IN	_	17	case	17:case	_
17	response	response	NOUN	NN	Number=Sing	15	nmod	15:nmod:of	Entity=time-81)(abstract-80)
18	(	(	PUNCT	-LRB-	_	19	punct	19:punct	Discourse=restatement:40->39
19	DOR	DOR	PROPN	NNP	Number=Sing	15	appos	15:appos	Entity=(abstract-82)
20	)	)	PUNCT	-RRB-	_	19	punct	19:punct	_
21	per	per	ADP	IN	_	23	case	23:case	Discourse=same_unit:41->39
22	investigator	investigator	NOUN	NN	Number=Sing	23	compound	23:compound	Entity=(abstract-63(person-83)
23	assessment	assessment	NOUN	NN	Number=Sing	15	nmod	15:nmod:per	Entity=abstract-63)
24	,	,	PUNCT	,	_	26	punct	26:punct	_
25	and	and	CCONJ	CC	_	26	cc	26:cc	_
26	OS	OS	NOUN	NNS	Number=Plur	6	conj	6:conj:and	Entity=abstract-53)(abstract-84)
27	.	.	PUNCT	.	_	6	punct	6:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-14
# text = The assessments of the tumor response across the studies were performed using Response Evaluation Criteria in Solid Tumors ( RECIST ) version 1.1 .
1	The	the	DET	DT	Definite=Def|PronType=Art	2	det	2:det	Discourse=elaboration:42->35|Entity=(abstract-85
2	assessments	assessment	NOUN	NNS	Number=Plur	11	nsubj:pass	11:nsubj:pass|12:nsubj:xsubj	_
3	of	of	ADP	IN	_	6	case	6:case	_
4	the	the	DET	DT	Definite=Def|PronType=Art	6	det	6:det	Entity=(abstract-80
5	tumor	tumor	NOUN	NN	Number=Sing	6	compound	6:compound	Entity=(abstract-86)
6	response	response	NOUN	NN	Number=Sing	2	nmod	2:nmod:of	Entity=abstract-80)
7	across	across	ADP	IN	_	9	case	9:case	_
8	the	the	DET	DT	Definite=Def|PronType=Art	9	det	9:det	Entity=(abstract-18
9	studies	study	NOUN	NNS	Number=Plur	2	nmod	2:nmod:across	Entity=abstract-85)abstract-18)
10	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	11	aux:pass	11:aux:pass	_
11	performed	perform	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
12	using	use	VERB	VBG	VerbForm=Ger	11	xcomp	11:xcomp	Discourse=means:43->42
13	Response	Response	PROPN	NNP	Number=Sing	15	compound	15:compound	Entity=(abstract-87(abstract-80)
14	Evaluation	Evaluation	PROPN	NNP	Number=Sing	15	compound	15:compound	Entity=(abstract-88)
15	Criteria	Criteria	PROPN	NNP	Number=Sing	12	obj	12:obj	_
16	in	in	ADP	IN	_	18	case	18:case	_
17	Solid	solid	ADJ	NNP	Number=Sing	18	amod	18:amod	Entity=(abstract-89
18	Tumors	Tumor	PROPN	NNPS	Number=Plur	15	nmod	15:nmod:in	Entity=abstract-87)abstract-89)
19	(	(	PUNCT	-LRB-	_	20	punct	20:punct	Discourse=restatement:44->43
20	RECIST	Recist	PROPN	NNP	Number=Sing	15	appos	15:appos	Entity=(abstract-87)
21	)	)	PUNCT	-RRB-	_	20	punct	20:punct	_
22	version	version	NOUN	NN	Number=Sing	15	appos	15:appos	Discourse=same_unit:45->42|Entity=(abstract-87
23	1.1	1.1	NUM	CD	NumForm=Digit|NumType=Card	22	nummod	22:nummod	Entity=abstract-87)
24	.	.	PUNCT	.	_	11	punct	11:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-15
# text = The safety comparisons were made using the adverse event ( any untoward medical occurrence regardless of causal relationship ) and adverse drug reaction ( noxious and unintended responses with at least a reasonable possibility of a causal relationship ) data .
1	The	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	Discourse=elaboration:46->42|Entity=(abstract-50
2	safety	safety	NOUN	NN	Number=Sing	3	compound	3:compound	Entity=(abstract-8)
3	comparisons	comparison	NOUN	NNS	Number=Plur	5	nsubj:pass	5:nsubj:pass|6:nsubj:xsubj	Entity=abstract-50)
4	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	5	aux:pass	5:aux:pass	_
5	made	make	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
6	using	use	VERB	VBG	VerbForm=Ger	5	xcomp	5:xcomp	Discourse=means:47->46
7	the	the	DET	DT	Definite=Def|PronType=Art	9	det	9:det	Entity=(event-41
8	adverse	adverse	ADJ	JJ	Degree=Pos	9	amod	9:amod	_
9	event	event	NOUN	NN	Number=Sing	6	obj	6:obj	Entity=event-41)
10	(	(	PUNCT	-LRB-	_	14	punct	14:punct	Discourse=elaboration:48->47
11	any	any	DET	DT	_	14	det	14:det	Entity=(event-41
12	untoward	untoward	ADJ	JJ	Degree=Pos|Polarity=Neg	14	amod	14:amod	_
13	medical	medical	ADJ	JJ	Degree=Pos	14	amod	14:amod	_
14	occurrence	occurrence	NOUN	NN	Number=Sing	9	appos	9:appos	_
15	regardless	regardless	ADV	RB	Degree=Pos	14	amod	14:amod	Entity=event-41)
16	of	of	ADP	IN	_	18	case	18:case	_
17	causal	causal	ADJ	JJ	Degree=Pos	18	amod	18:amod	Entity=(abstract-90
18	relationship	relationship	NOUN	NN	Number=Sing	15	obl	15:obl:of	Entity=abstract-90)
19	)	)	PUNCT	-RRB-	_	14	punct	14:punct	_
20	and	and	CCONJ	CC	_	40	cc	40:cc	Discourse=same_unit:49->47
21	adverse	adverse	ADJ	JJ	Degree=Pos	23	amod	23:amod	Entity=(event-91
22	drug	drug	NOUN	NN	Number=Sing	23	compound	23:compound	Entity=(substance-69)
23	reaction	reaction	NOUN	NN	Number=Sing	9	conj	6:obj|9:conj	Entity=event-91)
24	(	(	PUNCT	-LRB-	_	28	punct	28:punct	Discourse=elaboration:50->49
25	noxious	noxious	ADJ	JJ	Degree=Pos	28	amod	28:amod	Entity=(abstract-92
26	and	and	CCONJ	CC	_	27	cc	27:cc	_
27	unintended	unintended	ADJ	JJ	Degree=Pos|Polarity=Neg	25	conj	25:conj:and|28:amod	_
28	responses	response	NOUN	NNS	Number=Plur	23	appos	23:appos	_
29	with	with	ADP	IN	_	34	case	34:case	_
30	at	at	ADP	IN	_	31	case	31:case	_
31	least	least	ADJ	JJS	Degree=Sup	34	advmod	34:advmod	Entity=(abstract-93
32	a	a	DET	DT	Definite=Ind|PronType=Art	34	det	34:det	_
33	reasonable	reasonable	ADJ	JJ	Degree=Pos	34	amod	34:amod	_
34	possibility	possibility	NOUN	NN	Number=Sing	28	nmod	28:nmod:with	_
35	of	of	ADP	IN	_	38	case	38:case	_
36	a	a	DET	DT	Definite=Ind|PronType=Art	38	det	38:det	Entity=(abstract-90
37	causal	causal	ADJ	JJ	Degree=Pos	38	amod	38:amod	_
38	relationship	relationship	NOUN	NN	Number=Sing	34	nmod	34:nmod:of	Entity=abstract-92)abstract-93)abstract-90)
39	)	)	PUNCT	-RRB-	_	28	punct	28:punct	_
40	data	datum	NOUN	NNS	Number=Plur	6	obj	6:obj	Discourse=same_unit:51->50|Entity=(abstract-6)
41	.	.	PUNCT	.	_	5	punct	5:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-16
# text = The adverse event data included the overall summaries ( comprising all-grade , serious , and grade 3/4 AEs , and AEs leading to death , dose interruption/modification , and discontinuation ) and the incidence of specific all-grade and grade 3/4 AEs by individual preferred terms per the MedDRA dictionary .
1	The	the	DET	DT	Definite=Def|PronType=Art	4	det	4:det	Discourse=joint:52->9|Entity=(abstract-6
2	adverse	adverse	ADJ	JJ	Degree=Pos	3	amod	3:amod	Entity=(event-41
3	event	event	NOUN	NN	Number=Sing	4	compound	4:compound	Entity=event-41)
4	data	datum	NOUN	NNS	Number=Plur	5	nsubj	5:nsubj	Entity=abstract-6)
5	included	include	VERB	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	0	root	0:root	_
6	the	the	DET	DT	Definite=Def|PronType=Art	8	det	8:det	Entity=(abstract-94
7	overall	overall	ADJ	JJ	Degree=Pos	8	amod	8:amod	_
8	summaries	summary	NOUN	NNS	Number=Plur	5	obj	5:obj	_
9	(	(	PUNCT	-LRB-	_	10	punct	10:punct	Discourse=elaboration:53->52
10	comprising	comprise	VERB	VBG	VerbForm=Ger	8	acl	8:acl	_
11	all-grade	all-grade	ADJ	JJ	Degree=Pos	18	amod	18:amod	Entity=(abstract-95
12	,	,	PUNCT	,	_	13	punct	13:punct	_
13	serious	serious	ADJ	JJ	Degree=Pos	11	conj	11:conj:and|18:amod	_
14	,	,	PUNCT	,	_	11	punct	11:punct	_
15	and	and	CCONJ	CC	_	17	cc	17:cc	_
16	grade	grade	NOUN	NN	Number=Sing	17	compound	17:compound	Entity=(abstract-96)
17	3/4	3/4	NUM	CD	NumForm=Word|NumType=Card	18	compound	18:compound	_
18	AEs	ae	NOUN	NNS	Number=Plur	10	obj	10:obj	_
19	,	,	PUNCT	,	_	21	punct	21:punct	_
20	and	and	CCONJ	CC	_	21	cc	21:cc	_
21	AEs	ae	NOUN	NN	Number=Sing	11	conj	11:conj:and|18:compound	_
22	leading	lead	VERB	VBG	VerbForm=Ger	21	acl	21:acl	Discourse=elaboration:54->53
23	to	to	ADP	IN	_	24	case	24:case	_
24	death	death	NOUN	NN	Number=Sing	22	obl	22:obl:to	Entity=(event-97)
25	,	,	PUNCT	,	_	27	punct	27:punct	_
26	dose	dose	NOUN	NN	Number=Sing	27	compound	27:compound	Entity=(event-98(abstract-99)
27	interruption/modification	interruption/modification	NOUN	NN	Number=Sing	24	conj	22:obl:to|24:conj	Entity=event-98)
28	,	,	PUNCT	,	_	30	punct	30:punct	_
29	and	and	CCONJ	CC	_	30	cc	30:cc	_
30	discontinuation	discontinuation	NOUN	NN	Number=Sing	27	conj	24:conj|27:conj:and	Entity=abstract-95)(event-100)
31	)	)	PUNCT	-RRB-	_	10	punct	10:punct	Entity=abstract-94)
32	and	and	CCONJ	CC	_	34	cc	34:cc	Discourse=same_unit:55->52
33	the	the	DET	DT	Definite=Def|PronType=Art	34	det	34:det	Entity=(abstract-101
34	incidence	incidence	NOUN	NN	Number=Sing	8	conj	5:obj|8:conj:and	_
35	of	of	ADP	IN	_	41	case	41:case	_
36	specific	specific	ADJ	JJ	Degree=Pos	41	amod	41:amod	Entity=(abstract-95
37	all-grade	all-grade	ADJ	JJ	Degree=Pos	41	amod	41:amod	_
38	and	and	CCONJ	CC	_	40	cc	40:cc	_
39	grade	grade	NOUN	NN	Number=Sing	37	conj	37:conj|41:compound	_
40	3/4	3/4	NUM	CD	NumForm=Word|NumType=Card	39	flat	39:flat	_
41	AEs	ae	NOUN	NNS	Number=Plur	34	nmod	34:nmod:of	Entity=abstract-95)
42	by	by	ADP	IN	_	45	case	45:case	_
43	individual	individual	ADJ	JJ	Degree=Pos	45	amod	45:amod	Entity=(abstract-102
44	preferred	prefer	VERB	VBN	Tense=Past|VerbForm=Part	45	amod	45:amod	_
45	terms	term	NOUN	NNS	Number=Plur	34	nmod	34:nmod:by	_
46	per	per	ADP	IN	_	49	case	49:case	_
47	the	the	DET	DT	Definite=Def|PronType=Art	49	det	49:det	Entity=(abstract-103
48	MedDRA	MedDRA	PROPN	NNP	Number=Sing	49	compound	49:compound	Entity=(person-104)
49	dictionary	dictionary	NOUN	NN	Number=Sing	45	nmod	45:nmod:per	Entity=abstract-101)abstract-102)abstract-103)
50	.	.	PUNCT	.	_	5	punct	5:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-17
# text = All studies utilized the National Cancer Institute ( NCI ) Common Terminology Criteria for Adverse Events ( CTCAE ) to assess severity .
1	All	all	DET	DT	_	2	det	2:det	Discourse=joint:56->9|Entity=(abstract-18
2	studies	study	NOUN	NNS	Number=Plur	3	nsubj	3:nsubj	Entity=abstract-18)
3	utilized	utilize	VERB	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	0	root	0:root	_
4	the	the	DET	DT	Definite=Def|PronType=Art	13	det	13:det	Entity=(abstract-87
5	National	National	PROPN	NNP	Number=Sing	7	compound	7:compound	Entity=(organization-105
6	Cancer	Cancer	PROPN	NNP	Number=Sing	7	compound	7:compound	_
7	Institute	Institute	PROPN	NNP	Number=Sing	13	compound	13:compound	Entity=organization-105)
8	(	(	PUNCT	-LRB-	_	9	punct	9:punct	Discourse=restatement:57->56
9	NCI	NCI	PROPN	NNP	Number=Sing	7	appos	7:appos	Entity=(organization-105)
10	)	)	PUNCT	-RRB-	_	9	punct	9:punct	_
11	Common	Common	ADJ	NNP	Number=Sing	12	amod	12:amod	Discourse=same_unit:58->56|Entity=(abstract-106
12	Terminology	Terminology	PROPN	NNP	Number=Sing	13	compound	13:compound	Entity=abstract-106)
13	Criteria	Criteria	PROPN	NNP	Number=Sing	3	obj	3:obj	_
14	for	for	ADP	IN	_	16	case	16:case	_
15	Adverse	Adverse	ADJ	NNP	Number=Sing	16	amod	16:amod	Entity=(abstract-107
16	Events	Events	PROPN	NNPS	Number=Plur	13	nmod	13:nmod:for	Entity=abstract-87)abstract-107)
17	(	(	PUNCT	-LRB-	_	18	punct	18:punct	Discourse=restatement:59->58
18	CTCAE	CTCAE	PROPN	NNP	Number=Sing	16	appos	16:appos	Entity=(abstract-107)
19	)	)	PUNCT	-RRB-	_	18	punct	18:punct	_
20	to	to	PART	TO	_	21	mark	21:mark	Discourse=purpose:60->58
21	assess	assess	VERB	VB	VerbForm=Inf	3	advcl	3:advcl:to	_
22	severity	severity	NOUN	NN	Number=Sing	21	obj	21:obj	Entity=(abstract-108)
23	.	.	PUNCT	.	_	3	punct	3:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-18
# text = The coBRIM and COMBI-v trials used version 4.0 , whereas the COLUMBUS trial used version 4.03 .
1	The	the	DET	DT	Definite=Def|PronType=Art	5	det	5:det	Discourse=joint:61->9|Entity=(event-56
2	coBRIM	coBRIM	PROPN	NNP	Number=Sing	5	compound	5:compound	Entity=(abstract-20)
3	and	and	CCONJ	CC	_	4	cc	4:cc	_
4	COMBI-v	COMBI-v	PROPN	NNP	Number=Sing	2	conj	2:conj:and|5:compound	Entity=(abstract-39)
5	trials	trial	NOUN	NNS	Number=Plur	6	nsubj	6:nsubj	Entity=event-56)
6	used	use	VERB	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	0	root	0:root	_
7	version	version	NOUN	NN	Number=Sing	6	obj	6:obj	Entity=(abstract-109
8	4.0	4.0	NUM	CD	NumForm=Digit|NumType=Card	7	nummod	7:nummod	Entity=abstract-109)
9	,	,	PUNCT	,	_	14	punct	14:punct	_
10	whereas	whereas	SCONJ	IN	_	14	mark	14:mark	Discourse=antithesis:62->61
11	the	the	DET	DT	Definite=Def|PronType=Art	13	det	13:det	Entity=(event-41
12	COLUMBUS	Columbus	PROPN	NNP	Number=Sing	13	compound	13:compound	Entity=(place-75)
13	trial	trial	NOUN	NN	Number=Sing	14	nsubj	14:nsubj	Entity=event-41)
14	used	use	VERB	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	6	advcl	6:advcl:whereas	_
15	version	version	NOUN	NN	Number=Sing	14	obj	14:obj	Entity=(abstract-110
16	4.03	4.03	NUM	CD	NumForm=Digit|NumType=Card	15	nummod	15:nummod	Entity=abstract-110)
17	.	.	PUNCT	.	_	6	punct	6:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-19
# text = The primary source of data on adverse drug reactions was the available U.S. prescribing information .
1	The	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	Discourse=joint:63->9|Entity=(abstract-111
2	primary	primary	ADJ	JJ	Degree=Pos	3	amod	3:amod	_
3	source	source	NOUN	NN	Number=Sing	15	nsubj	15:nsubj	_
4	of	of	ADP	IN	_	5	case	5:case	_
5	data	datum	NOUN	NNS	Number=Plur	3	nmod	3:nmod:of	Entity=(abstract-6
6	on	on	ADP	IN	_	9	case	9:case	_
7	adverse	adverse	ADJ	JJ	Degree=Pos	9	amod	9:amod	Entity=(event-112
8	drug	drug	NOUN	NN	Number=Sing	9	compound	9:compound	Entity=(substance-69)
9	reactions	reaction	NOUN	NNS	Number=Plur	5	nmod	5:nmod:on	Entity=abstract-111)abstract-6)event-112)
10	was	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	15	cop	15:cop	_
11	the	the	DET	DT	Definite=Def|PronType=Art	15	det	15:det	Entity=(abstract-111
12	available	available	ADJ	JJ	Degree=Pos	15	amod	15:amod	_
13	U.S.	U.S.	PROPN	NNP	Abbr=Yes|Number=Sing	15	compound	15:compound	Entity=(place-67)
14	prescribing	prescribe	VERB	VBG	VerbForm=Ger	15	amod	15:amod	_
15	information	information	NOUN	NN	Number=Sing	0	root	0:root	Entity=abstract-111)
16	.	.	PUNCT	.	_	15	punct	15:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-20
# text = The additional adverse event data for the dabrafenib plus trametinib combination was derived from the COMBI-d trial .
1	The	the	DET	DT	Definite=Def|PronType=Art	5	det	5:det	Discourse=joint:64->9|Entity=(abstract-6
2	additional	additional	ADJ	JJ	Degree=Pos	5	amod	5:amod	_
3	adverse	adverse	ADJ	JJ	Degree=Pos	4	amod	4:amod	Entity=(event-41
4	event	event	NOUN	NN	Number=Sing	5	compound	5:compound	Entity=event-41)
5	data	datum	NOUN	NNS	Number=Plur	13	nsubj:pass	13:nsubj:pass	_
6	for	for	ADP	IN	_	11	case	11:case	_
7	the	the	DET	DT	Definite=Def|PronType=Art	8	det	8:det	Entity=(abstract-11(animal-30
8	dabrafenib	dabrafenib	NOUN	NN	Number=Sing	11	compound	11:compound	Entity=animal-30)
9	plus	plus	CCONJ	CC	_	11	cc	11:cc	_
10	trametinib	trametinib	NOUN	NN	Number=Sing	11	compound	11:compound	Entity=(object-31)
11	combination	combination	NOUN	NN	Number=Sing	5	nmod	5:nmod:for	Entity=abstract-6)abstract-11)
12	was	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	13	aux:pass	13:aux:pass	_
13	derived	derive	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
14	from	from	ADP	IN	_	17	case	17:case	_
15	the	the	DET	DT	Definite=Def|PronType=Art	17	det	17:det	Entity=(event-41
16	COMBI-d	COMBI-d	PROPN	NNP	Number=Sing	17	compound	17:compound	Entity=(abstract-28)
17	trial	trial	NOUN	NN	Number=Sing	13	obl	13:obl:from	Entity=event-41)
18	.	.	PUNCT	.	_	13	punct	13:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-21
# text = For the cobimetinib plus vemurafenib combination , the coBRIM trial was utilized .
1	For	for	ADP	IN	_	6	case	6:case	Discourse=elaboration:65->64
2	the	the	DET	DT	Definite=Def|PronType=Art	6	det	6:det	Entity=(abstract-11
3	cobimetinib	cobimetinib	NOUN	NN	Number=Sing	6	compound	6:compound	Entity=(abstract-23(substance-24)
4	plus	plus	CCONJ	CC	_	5	cc	5:cc	_
5	vemurafenib	vemurafenib	NOUN	NN	Number=Sing	3	conj	3:conj:plus|6:compound	Entity=abstract-23)(person-25)
6	combination	combination	NOUN	NN	Number=Sing	12	obl	12:obl:for	Entity=abstract-11)
7	,	,	PUNCT	,	_	6	punct	6:punct	_
8	the	the	DET	DT	Definite=Def|PronType=Art	10	det	10:det	Entity=(event-41
9	coBRIM	coBRIM	PROPN	NNP	Number=Sing	10	compound	10:compound	Entity=(abstract-20)
10	trial	trial	NOUN	NN	Number=Sing	12	nsubj:pass	12:nsubj:pass	Entity=event-41)
11	was	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	12	aux:pass	12:aux:pass	_
12	utilized	utilize	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
13	.	.	PUNCT	.	_	12	punct	12:punct	_

# s_type = decl
# sent_id = AMALGUM_academic_braf-22
# text = The COLUMBUS study was utilized as a source of additional information for adverse events for the encorafenib plus binimetinib combination .
1	The	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	Discourse=joint:66->9|Entity=(abstract-113
2	COLUMBUS	Columbus	PROPN	NNP	Number=Sing	3	compound	3:compound	Entity=(place-75)
3	study	study	NOUN	NN	Number=Sing	5	nsubj:pass	5:nsubj:pass	Entity=abstract-113)
4	was	be	AUX	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	5	aux:pass	5:aux:pass	_
5	utilized	utilize	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
6	as	as	ADP	IN	_	8	case	8:case	_
7	a	a	DET	DT	Definite=Ind|PronType=Art	8	det	8:det	Entity=(abstract-114
8	source	source	NOUN	NN	Number=Sing	5	obl	5:obl:as	_
9	of	of	ADP	IN	_	11	case	11:case	_
10	additional	additional	ADJ	JJ	Degree=Pos	11	amod	11:amod	Entity=(abstract-111
11	information	information	NOUN	NN	Number=Sing	8	nmod	8:nmod:of	_
12	for	for	ADP	IN	_	14	case	14:case	_
13	adverse	adverse	ADJ	JJ	Degree=Pos	14	amod	14:amod	Entity=(event-115
14	events	event	NOUN	NNS	Number=Plur	11	nmod	11:nmod:for	_
15	for	for	ADP	IN	_	20	case	20:case	_
16	the	the	DET	DT	Definite=Def|PronType=Art	17	det	17:det	Entity=(abstract-11(abstract-42
17	encorafenib	encorafenib	NOUN	NN	Number=Sing	20	compound	20:compound	Entity=abstract-42)
18	plus	plus	CCONJ	CC	_	19	cc	19:cc	_
19	binimetinib	binimetinib	NOUN	NN	Number=Sing	17	conj	17:conj:plus|20:compound	Entity=(abstract-43)
20	combination	combination	NOUN	NN	Number=Sing	14	nmod	14:nmod:for	Entity=abstract-114)abstract-111)event-115)abstract-11)
21	.	.	PUNCT	.	_	5	punct	5:punct	_

